Key Takeaways:
CRISPR Therapeutics AG (NASDAQ:CRSP) reported a wider-than-expected first-quarter loss of $1.28 per share, missing Wall Street estimates by over 12 percent and overshadowing the strong commercial launch of its partnered gene-editing therapy, Casgevy.
The results stand in contrast to the progress reported by partner Vertex Pharmaceuticals (NASDAQ:VRTX), which leads the global commercialization of Casgevy. Vertex CEO Dr. Reshma Kewalramani recently described the launch as having "very strong visibility" for the rest of 2026.
The reported loss of $1.28 per share compares unfavorably to the Zacks Consensus Estimate of a $1.14 loss, though it is an improvement from the $1.58 per share loss in the same quarter a year ago. The miss was unexpected, as pre-earnings data from Zacks had pointed to a high likelihood of an EPS beat. Revenue figures for the quarter were not disclosed in the initial release.
The report puts investors in a difficult position, weighing a direct earnings miss against the positive, revenue-generating launch of the company's core asset by a partner. While CRISPR's bottom line disappointed, Vertex's report of $43 million in Q1 Casgevy sales shows the therapy is gaining traction, a crucial long-term validation of CRISPR's technology platform.
The underlying story for CRISPR Therapeutics remains intrinsically linked to the success of Casgevy, a one-time gene-editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia that it co-developed with Vertex. Under the terms of their agreement, Vertex leads the global commercialization and books the sales, providing a stream of revenue back to CRISPR.
Vertex reported that its Casgevy rollout is gaining momentum, with over 500 patients having initiated the treatment journey in the first quarter of 2026, generating $43 million in revenue. Vertex also noted progress on the reimbursement front, securing a pricing agreement in Germany during the quarter. The company expects Casgevy to contribute meaningfully toward a goal of more than $500 million in non-cystic fibrosis revenue this year, a positive signal for the therapy's long-term potential.
The first-quarter earnings miss was particularly notable because it defied analyst expectations. Heading into the report, the Zacks Earnings ESP (Expected Surprise Prediction) for CRISPR Therapeutics was a positive 28.88%, a combination that historically suggests a high probability of an earnings beat. This marks the second consecutive quarter the company has failed to meet consensus EPS estimates. The surprise miss suggests that while the top-line story for Casgevy is promising, the costs associated with CRISPR's own pipeline development and operations may be weighing on the bottom line more than analysts had modeled.
This article is for informational purposes only and does not constitute investment advice.
